Winton Group’s Standard BioTools LAB Stock Holding History

Winton Group’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-20,568	Closed	-$72K	–	1475
2019 Q4	$72K	Buy	+20,568	New	+$72.4K	﹤0.01%	1497

Other funds holding LAB

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Winton Group's LAB Position: Q1 2020 in Review

Winton Group sold out of Standard BioTools (LAB) in Q1 2020, closing a stake of 20,568 shares — an estimated $72K sold.

Winton Group first reported a position in LAB in Q4 2019 and held it in 1 quarter. The position peaked at $72K in Q4 2019. 103 funds tracked by Wall St. Rank hold LAB as of Q1 2020.

Winton Group reported no remaining Standard BioTools position as of Q1 2020 after selling out during the quarter.
Winton Group sold 20,568 Standard BioTools shares in Q1 2020, an estimated $72K.
Winton Group first reported a position in Standard BioTools in Q4 2019 and held it in 1 quarter.
Winton Group's Standard BioTools position peaked at $72K in Q4 2019.
103 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.